CSGALNACT2通过DUSP1调节MAPK/ERK通路来限制卵巢癌的迁移和入侵
Mingjun Ma1,2, Chao Wang1,2, Meixuan Wu3
1Department of Gynecology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, No.2699, Gaoke West Rd, Shanghai, 200092, China.
Cellular oncology (Dordrecht, Netherlands)
|December 11, 2023
概括
戈尔吉转移酶CSGALNACT2作为卵巢癌抑制基因,抑制瘤的进展和转移. 它的下调与预后不佳和免疫疗法益处降低相关,表明其作为生物标志物的潜力.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 卵巢癌是女性癌症相关死亡的主要原因.
- 在卵巢癌中戈尔吉转移酶CSGALNACT2的作用和表达还不清楚.
研究的目的:
- 研究CSGALNACT2在卵巢癌中的表达模式和功能作用.
- 探索CSGALNACT2作为预后生物标志物的潜力及其与免疫透和免疫治疗反应的关联.
主要方法:
- 利用癌症基因组图集和GEPIA数据库进行表达分析.
- 使用RNA-seq,qRT-PCR和免疫组织化学 (IHC) 来验证CSGALNACT2的表达.
- 进行了体外和体内实验,以评估CSGALNACT2对卵巢癌进展的功能影响.
- 进行了RNA-seq,KEGG通路分析,以及西部涂抹,以阐明潜在的分子机制.
主要成果:
- 在卵巢癌组织中,CSGALNACT2mRNA和蛋白质水平显著下调,随着癌症的进展而下降.
- 在体外和体内,CSGALNACT2抑制了卵巢癌细胞的迁移,入侵和生长.
- 抑制作用是由MAPK/ERK通路的DUSP1调制介导的.
- CSGALNACT2表达与免疫细胞透相关,并证明具有预后价值.
- 降低CSGALNACT2的调节与免疫治疗的益处减少有关.
结论:
- 在卵巢癌中,CSGALNACT2作为瘤抑制基因起作用,抑制其发展.
- CSGALNACT2有可能成为卵巢癌患者的预后生物标志物.
- 了解CSGALNACT2的作用可以为治疗策略提供信息,特别是关于免疫治疗反应.
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Cancer Cell Migration through Invadopodia
2.3K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.3K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K


